Lattice Biologics LtdTSXV:LBL.HView on Over The Counter Market
- LAST PRICE0.0400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0400
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lattice Biologics Ltd | 4.2M | -3.8x | --- |
Justera Health Ltd | 1.2M | -0.5x | --- |
Cloud DX Inc | 12.1M | -1.2x | --- |
NuGen Medical Devices Inc | 21.8M | -2.6x | --- |
Rapid Dose Therapeutics Corp | 34.7M | -5.7x | --- |
Gemina Laboratories Ltd | 42.5M | -11.3x | --- |
Company Information
Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.
Contact Information
- Headquarters
- 512 E. Madison Ave. Suite A1BELGRADE, MT, United States 59714
- Phone
- 406-570-2658
- Fax
- 480-563-0810
Executives
- Chief Executive Officer, Director
- Guy Cook
- Interim Chief Financial Officer
- Donna Medina
- Independent Director
- Kevin Loud
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2M |
|---|---|
Revenue (TTM) | $2.2M |
Shares Outstanding | 104.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.01 |
Book Value | $-0.07 |
P/E Ratio | -3.8x |
Price/Sales (TTM) | 1.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -30.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
